Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02918188

Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD

Chronic Graft-versus-host Disease Clinical Trial

Official title:
Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent Chronic Graft-versus-host-disease

Clinical Trial Summary

This study suggested that hydrogen has a potential as an effective and safe therapeutic agent on cGVHD.

Clinical Trial Description

The investigators will evaluate clinical response rate, time to treatment Failure (TTF), overall survival (OS), and toxicity in cGVHD patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02918188
Study type Interventional
Source Navy General Hospital, Beijing
Contact Liren Qian, M.D.
Phone +861066957676
Email qlr2007@126.com
Status Recruiting
Phase Phase 2
Start date January 2016
Completion date January 2031
View Details
See also
  Status Clinical Trial Phase
Completed NCT02991846 - A Prospective Observational Study for Evaluating CGVHD
Recruiting NCT02291770 - Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells Phase 3
Terminated NCT01226420 - Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease Phase 2
Active, not recruiting NCT02759731 - Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT01862965 - Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus Phase 2
Completed NCT02411474 - Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD N/A
Completed NCT02040623 - Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) Phase 2
Active, not recruiting NCT01158105 - Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) Phase 2
Terminated NCT01903473 - Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) Phase 2
Active, not recruiting NCT01366092 - Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Phase 2
Recruiting NCT05690971 - Psychosocial Mobile App for Chronic Graft-Versus-Host Disease N/A
Recruiting NCT01765660 - Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease Phase 2
Completed NCT01956903 - Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell. Phase 1/Phase 2
Terminated NCT03584516 - GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Phase 2/Phase 3
Recruiting NCT04692376 - MSC for Treatment of cGVHD After Allo-HSCT Phase 2
Completed NCT02966301 - Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide Phase 2
Terminated NCT01898377 - Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children Phase 2
Recruiting NCT02611180 - Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Recruiting NCT02669251 - Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Active, not recruiting NCT01161628 - Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) Phase 2